[go: up one dir, main page]

CA2373994A1 - Excipient en emulsion pour medicaments faiblement solubles - Google Patents

Excipient en emulsion pour medicaments faiblement solubles Download PDF

Info

Publication number
CA2373994A1
CA2373994A1 CA002373994A CA2373994A CA2373994A1 CA 2373994 A1 CA2373994 A1 CA 2373994A1 CA 002373994 A CA002373994 A CA 002373994A CA 2373994 A CA2373994 A CA 2373994A CA 2373994 A1 CA2373994 A1 CA 2373994A1
Authority
CA
Canada
Prior art keywords
paclitaxel
composition according
tocopherol
emulsion
tpgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002373994A
Other languages
English (en)
Inventor
Karel J. Lambert
Panayiotis P. Constantinides
Steven C. Quay
Alexander K. Tustian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achieve Life Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/317,499 external-priority patent/US6660286B1/en
Application filed by Individual filed Critical Individual
Publication of CA2373994A1 publication Critical patent/CA2373994A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention se rapporte à une émulsion comportant un ou plusieurs tocols et un co-solvant et stabilisée par des tensioactifs biocompatibles, qui est utilisée en tant qu'excipient ou support de médicaments thérapeutiques. Cette émulsion ne contient pratiquement pas d'éthanol et elle peut être administrée à des animaux ou des humains selon différentes voies. Ladite émulsion comporte également de la vitamine E associée à du polyéthylène glycol (PEG). Le .alpha.-tocophérol associé à du PEG comporte des sous-unités de polyéthylène glycol reliées par un diester d'acide succinique au noyau hydroxyle de la vitamine E et il sert de tensioactif primaire, de stabilisateur et de solvant secondaire dans les émulsions de tocol.
CA002373994A 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles Abandoned CA2373994A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31749599A 1999-05-24 1999-05-24
US09/317,499 1999-05-24
US09/317,495 1999-05-24
US09/317,499 US6660286B1 (en) 1997-01-07 1999-05-24 Emulsion vehicle for poorly soluble drugs
US15612899P 1999-09-27 1999-09-27
US60/156,128 1999-09-27
PCT/US2000/013572 WO2000071163A1 (fr) 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles

Publications (1)

Publication Number Publication Date
CA2373994A1 true CA2373994A1 (fr) 2000-11-30

Family

ID=27387807

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002373994A Abandoned CA2373994A1 (fr) 1999-05-24 2000-05-17 Excipient en emulsion pour medicaments faiblement solubles

Country Status (9)

Country Link
EP (1) EP1185301A1 (fr)
JP (1) JP2003500368A (fr)
KR (1) KR20070058028A (fr)
AU (1) AU5273200A (fr)
BR (1) BR0010794A (fr)
CA (1) CA2373994A1 (fr)
MX (1) MXPA01011981A (fr)
TW (1) TWI290052B (fr)
WO (1) WO2000071163A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402804B2 (en) 2004-06-02 2016-08-02 CARDINAL HEALTH SWITZERLAND 515 GmbH Injectable formulations of taxanes for cad treatment

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
JP2003513019A (ja) * 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス，インコーポレイテッド トコール可溶性治療剤の組成物
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
WO2002026208A2 (fr) * 2000-09-27 2002-04-04 Sonus Pharmaceuticals, Inc. Excipient emulsionne pour medicaments a faible solubilite
EP1337273A2 (fr) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Formulations pharmaceutiques contenant du paclitaxel, ses derives et ses sels pharmaceutiquement acceptables
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
FR2820975B1 (fr) * 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
EP1458358A1 (fr) * 2001-12-13 2004-09-22 Ranbaxy Laboratories, Ltd. Formulation topique stable de clarithromycine
JP2005526705A (ja) * 2001-12-19 2005-09-08 リサーチ　ディベロップメント　ファンデーション ビタミンｅに基づく化合物のリポソームによる送達方法
CA2472578A1 (fr) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combinaison anticancereuse et son utilisation
AU2003234670B2 (en) 2002-05-24 2010-06-10 Angiotech International Ag Compositions and methods for coating medical implants
FR2840614B1 (fr) 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
EP2135868A1 (fr) 2002-11-07 2009-12-23 Kosan Biosciences Incorporated Trans-9,10-didéhydroepothilones c et d, leurs dérivés et un procédé pour leur préparation.
WO2004073692A1 (fr) * 2003-02-18 2004-09-02 Yamashita, Shinji Capsule dure de medicament peu hydrosoluble
US8802116B2 (en) 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
FR2855521B1 (fr) 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
EP1498120A1 (fr) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Formulation semi-solide pour l'administration orale du taxol
EP1661556A4 (fr) * 2003-08-20 2010-05-19 Ajinomoto Kk Preparation medicinale ayant des proprietes de dissolution ameliorees
EP1510206A1 (fr) * 2003-08-29 2005-03-02 Novagali Pharma SA Formulation huileuse auto-émulsifiable pour l'administration de principes actifs peu solubles dans l'eau
RU2340616C2 (ru) * 2003-10-29 2008-12-10 Сонус Фармасьютикалз, Инк. Токоферол-модифицированные терапевтические лекарственные соединения
TW200522978A (en) * 2003-10-29 2005-07-16 Sonus Pharma Inc Tocopherol-modified therapeutic drug compounds
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060009504A1 (en) * 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
FR2879932B1 (fr) * 2004-12-27 2007-03-23 Aventis Pharma Sa Formulations injectable ou administrable par voie orale de derives d'azetidine
KR101387456B1 (ko) * 2005-02-09 2014-04-21 산텐 세이야꾸 가부시키가이샤 질환 또는 상태의 치료를 위한 액체 제제
PT2301531T (pt) 2005-02-18 2018-07-30 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
JP4929158B2 (ja) * 2005-03-14 2012-05-09 株式会社大塚製薬工場 難水溶性薬物を含有する医薬組成物
CA2604473A1 (fr) 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Methode pour traiter un myelome multiple au moyen de 17-aag ou de 17-ag ou d'un promedicament de l'un ou de l'autre
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
CA2620374C (fr) * 2005-09-28 2012-12-11 Thomas Meyer Compositions pharmaceutiques pour le traitement de pathologies de l'oreille interne
CN101400337A (zh) * 2006-03-10 2009-04-01 拉伯斯威斯股份有限公司 物质的增溶、分散和稳定方法、由此方法制备的产品及其用途
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
JP5301995B2 (ja) 2006-08-29 2013-09-25 富士フイルム株式会社 難水溶性化合物封入親水性マトリックスおよびその製法
WO2008088037A1 (fr) * 2007-01-18 2008-07-24 National University Corporation Chiba University Préparation médicinale à particules fines
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
WO2009084801A1 (fr) * 2007-12-31 2009-07-09 Samyang Corporation Composition micellaire de copolymère à blocs amphiphiles contenant du taxane et son procédé de fabrication
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2609640T3 (es) * 2009-08-14 2017-04-21 Opko Health, Inc Formulaciones intravenosas de rolapitant
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US8591942B2 (en) 2009-09-23 2013-11-26 Indu JAVERI Methods for the preparation of liposomes comprising docetaxel
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
US20110144578A1 (en) * 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
CN102101863B (zh) 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP5876467B2 (ja) * 2010-03-17 2016-03-02 クローダ，インコーポレイティド ポリマー界面活性剤
NZ703047A (en) 2010-03-29 2016-11-25 Abraxis Bioscience Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
EP2552415B1 (fr) 2010-03-29 2016-09-07 Abraxis BioScience, LLC Méthodes de traitement du cancer
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
AU2011287873B2 (en) * 2010-08-04 2014-09-25 Grünenthal GmbH Pharmaceutical dosage form comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
PL2701684T3 (pl) 2011-04-28 2018-09-28 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (fr) 2014-08-28 2016-03-03 Lipocine Inc. Esters de (17-β)-hydroxy-4-androstène-3-one biodisponibles à l'état solide
WO2016205423A2 (fr) 2015-06-15 2016-12-22 Lipocine Inc. Composition et méthode pour l'administration orale de promédicaments androgènes
CN105267145B (zh) * 2015-11-01 2019-06-21 袁旭东 双膦酸盐的自乳化配方和相关剂型
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
US20200093751A1 (en) * 2016-06-28 2020-03-26 Der-Yang Tien Chemoprotective/chemoactive nanodroplets and methods of use thereof
JP2018024592A (ja) * 2016-08-09 2018-02-15 株式会社ブレインヘルス 抗生物質含有組成物
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3424493A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
EP3424494A1 (fr) * 2017-07-07 2019-01-09 SolMic Research GmbH Compositions de cannabinoïde stables
KR102197257B1 (ko) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 엔테카비어 지방산 에스테르 유도체 수성현탁액의 안정화 조성물
CA3107214A1 (fr) 2018-07-20 2020-01-23 Lipocine Inc. Maladie du foie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169846A (en) * 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
KR100239799B1 (ko) * 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ314060A (en) * 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
AU729724B2 (en) * 1997-04-18 2001-02-08 Taisho Pharmaceutical Co., Ltd. Microemulsion
JPH1149664A (ja) * 1997-04-18 1999-02-23 Taisho Pharmaceut Co Ltd マイクロエマルション
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9402804B2 (en) 2004-06-02 2016-08-02 CARDINAL HEALTH SWITZERLAND 515 GmbH Injectable formulations of taxanes for cad treatment

Also Published As

Publication number Publication date
WO2000071163A1 (fr) 2000-11-30
JP2003500368A (ja) 2003-01-07
EP1185301A1 (fr) 2002-03-13
AU5273200A (en) 2000-12-12
MXPA01011981A (es) 2003-09-04
KR20070058028A (ko) 2007-06-07
TWI290052B (en) 2007-11-21
BR0010794A (pt) 2002-06-04

Similar Documents

Publication Publication Date Title
US6660286B1 (en) Emulsion vehicle for poorly soluble drugs
US7030155B2 (en) Emulsion vehicle for poorly soluble drugs
CA2373994A1 (fr) Excipient en emulsion pour medicaments faiblement solubles
WO1998030205A9 (fr) Excipient emulsionne pour medicaments faiblement solubles
US6245349B1 (en) Drug delivery compositions suitable for intravenous injection
Cannon et al. Emulsions, microemulsions, and lipid-based drug delivery systems for drug solubilization and delivery—Part I: parenteral applications
CN101926757B (zh) 一种难溶性药物的液体组合物及其制备方法
Kumbhar et al. D-ɑ-tocopheryl polyethylene glycol succinate: A review of multifarious applications in nanomedicines
WO1999004787A1 (fr) Emulsion de taxol
WO2002026208A2 (fr) Excipient emulsionne pour medicaments a faible solubilite
KR100754352B1 (ko) 난용성 약물용 에멀젼 부형제의 제조방법
AU2001280084B2 (en) Amphotericin b structured emulsion
AU5731498A (en) Emulsion vehicle for poorly soluble drugs
Cannon et al. 211 Emulsions, Microemulsions, and Lipid-Based Drug Delivery Systems for Drug Solubilization and Delivery—Part I: Parenteral Applications
Cannon et al. 10 Emulsions, Microemulsions, and Lipid-Based Drug
TW201223560A (en) Drug-loaded emulsion and the preparation method thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued